{
  "doc_id": "7_administrationofnutritionsupport_part2__82880b",
  "original_filename": "7_AdministrationofNutritionSupport,Part2.pdf",
  "md_path": "data/parsed/7_AdministrationofNutritionSupport,Part2/7_AdministrationofNutritionSupport,Part2.md",
  "rmd_path": "data/parsed/7_AdministrationofNutritionSupport,Part2/7_AdministrationofNutritionSupport,Part2.rmd",
  "blocks": [
    {
      "type": "heading",
      "level": 1,
      "section": "NUTRITION SUPPORT CERTIFICATE",
      "line": 0
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Administration of Nutrition Support, Part 2",
      "line": 2
    },
    {
      "type": "image",
      "section": "Administration of Nutrition Support, Part 2",
      "line": 4,
      "content": "![img-0.jpeg](images/412f1b1b557f1ba0.png)"
    },
    {
      "type": "text",
      "section": "Administration of Nutrition Support, Part 2",
      "line": 6,
      "preview": "Planned by the American Society of Health-System Pharmacists (ASHP) in collaboration with the Americ"
    },
    {
      "type": "text",
      "section": "Administration of Nutrition Support, Part 2",
      "line": 7,
      "preview": "(c)2022 American Society of Health-System Pharmacists, Inc. All rights reserved."
    },
    {
      "type": "text",
      "section": "Administration of Nutrition Support, Part 2",
      "line": 9,
      "preview": "No part of this publication may be reproduced or transmitted in any form or by any means, electronic"
    },
    {
      "type": "text",
      "section": "Administration of Nutrition Support, Part 2",
      "line": 11,
      "preview": "--- page 1 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "ADMINISTRATION OF NUTRITION SUPPORT PART 2",
      "line": 13
    },
    {
      "type": "text",
      "section": "ADMINISTRATION OF NUTRITION SUPPORT PART 2",
      "line": 15,
      "preview": "Todd W. Canada, Pharm.D., BCNSP, BCCCP, FASHP, FTSHP, FASPEN"
    },
    {
      "type": "text",
      "section": "ADMINISTRATION OF NUTRITION SUPPORT PART 2",
      "line": 16,
      "preview": "University of Texas MD Anderson"
    },
    {
      "type": "text",
      "section": "ADMINISTRATION OF NUTRITION SUPPORT PART 2",
      "line": 17,
      "preview": "Cancer Center"
    },
    {
      "type": "text",
      "section": "ADMINISTRATION OF NUTRITION SUPPORT PART 2",
      "line": 19,
      "preview": "NUTRITION SUPPORT CERTIFICATE"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "RELEVANT FINANCIAL RELATIONSHIP DISCLOSURE",
      "line": 21
    },
    {
      "type": "text",
      "section": "RELEVANT FINANCIAL RELATIONSHIP DISCLOSURE",
      "line": 23,
      "preview": "The following persons in control of this activity's content have relevant financial relationships:"
    },
    {
      "type": "text",
      "section": "RELEVANT FINANCIAL RELATIONSHIP DISCLOSURE",
      "line": 25,
      "preview": "- Andrew Mays: Fresenius Kabi, speaker"
    },
    {
      "type": "text",
      "section": "RELEVANT FINANCIAL RELATIONSHIP DISCLOSURE",
      "line": 27,
      "preview": "All other persons in control of content do not have any relevant financial relationships with an ine"
    },
    {
      "type": "text",
      "section": "RELEVANT FINANCIAL RELATIONSHIP DISCLOSURE",
      "line": 29,
      "preview": "As defined by the Standards of Integrity and Independence definition of ineligible company. All rele"
    },
    {
      "type": "text",
      "section": "RELEVANT FINANCIAL RELATIONSHIP DISCLOSURE",
      "line": 31,
      "preview": "--- page 2 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "LEARNING OBJECTIVES",
      "line": 33
    },
    {
      "type": "text",
      "section": "LEARNING OBJECTIVES",
      "line": 35,
      "preview": "- Outline safe medication administration practices with concurrent enteral or parenteral nutrition."
    },
    {
      "type": "text",
      "section": "LEARNING OBJECTIVES",
      "line": 36,
      "preview": "- Distinguish steps in managing total nutrient admixture vs. 2-in-1 parenteral nutrition with separa"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "KEY ABBREVIATIONS",
      "line": 39
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS",
      "line": 41,
      "preview": "- EN:"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS",
      "line": 42,
      "preview": "- GI:"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS",
      "line": 43,
      "preview": "- ILE:"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS",
      "line": 44,
      "preview": "- IV:"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS",
      "line": 45,
      "preview": "- PN:"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS",
      "line": 46,
      "preview": "- TNA: enteral nutrition"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS",
      "line": 47,
      "preview": "gastrointestinal"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS",
      "line": 48,
      "preview": "lipid injectable emulsion"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS",
      "line": 49,
      "preview": "intravenous"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS",
      "line": 50,
      "preview": "parenteral nutrition"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS",
      "line": 51,
      "preview": "total nutrient admixture"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS",
      "line": 53,
      "preview": "--- page 3 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "SELF-ASSESSMENT \\#1",
      "line": 55
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#1",
      "line": 57,
      "preview": "A 61-year-old male with Type 2 diabetes mellitus and benign prostatic hypertrophy is admitted with u"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#1",
      "line": 58,
      "preview": "A. Tamsulosin 0.4 mg daily"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#1",
      "line": 59,
      "preview": "B. Doxazosin 2 mg daily"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#1",
      "line": 60,
      "preview": "C. Metformin ER 2000 mg daily"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#1",
      "line": 61,
      "preview": "D. Metformin ER 500 mg TID"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "SELF-ASSESSMENT \\#2",
      "line": 63
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#2",
      "line": 65,
      "preview": "A 55-year-old female with acute myelogenous leukemia and typhlitis is receiving parenteral nutrition"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#2",
      "line": 66,
      "preview": "A. Acyclovir"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#2",
      "line": 67,
      "preview": "B. Amphotericin B"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#2",
      "line": 68,
      "preview": "C. Ondansetron"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#2",
      "line": 69,
      "preview": "D. Piperacillin/Tazobactam"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#2",
      "line": 71,
      "preview": "--- page 4 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "SAFE MEDICATION PRACTICES WITH EN",
      "line": 73
    },
    {
      "type": "text",
      "section": "SAFE MEDICATION PRACTICES WITH EN",
      "line": 75,
      "preview": "- Dependent on type of feeding tube used:"
    },
    {
      "type": "text",
      "section": "SAFE MEDICATION PRACTICES WITH EN",
      "line": 76,
      "preview": "- Gastrostomy"
    },
    {
      "type": "text",
      "section": "SAFE MEDICATION PRACTICES WITH EN",
      "line": 77,
      "preview": "- Transgastric jejunostomy"
    },
    {
      "type": "text",
      "section": "SAFE MEDICATION PRACTICES WITH EN",
      "line": 78,
      "preview": "- Be aware the use of each lumen and avoid medication administration into stomach when concerns abou"
    },
    {
      "type": "text",
      "section": "SAFE MEDICATION PRACTICES WITH EN",
      "line": 79,
      "preview": "- $50 \\%$ of patients experience ingredient-related diarrhea when using enteral access tubes for med"
    },
    {
      "type": "text",
      "section": "SAFE MEDICATION PRACTICES WITH EN",
      "line": 80,
      "preview": "- Many liquid formulations of medications have osmolalities far exceeding that of the GI tract"
    },
    {
      "type": "text",
      "section": "SAFE MEDICATION PRACTICES WITH EN",
      "line": 81,
      "preview": "- Diarrhea, cramping, abdominal distention, and vomiting"
    },
    {
      "type": "text",
      "section": "SAFE MEDICATION PRACTICES WITH EN",
      "line": 83,
      "preview": "McIntyre CM et al. AmJ Health-Syst Pharm. 2014;71:549-56."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "SAFE MEDICATION PRACTICES WITH EN, CONT.",
      "line": 85
    },
    {
      "type": "text",
      "section": "SAFE MEDICATION PRACTICES WITH EN, CONT.",
      "line": 87,
      "preview": "- Nasoduodenal"
    },
    {
      "type": "text",
      "section": "SAFE MEDICATION PRACTICES WITH EN, CONT.",
      "line": 88,
      "preview": "- Nasojejunal"
    },
    {
      "type": "text",
      "section": "SAFE MEDICATION PRACTICES WITH EN, CONT.",
      "line": 89,
      "preview": "- Jejunostomy"
    },
    {
      "type": "text",
      "section": "SAFE MEDICATION PRACTICES WITH EN, CONT.",
      "line": 90,
      "preview": "- Significant risk of drug-nutrient interactions as both food (enteral nutrition) and medications ar"
    },
    {
      "type": "text",
      "section": "SAFE MEDICATION PRACTICES WITH EN, CONT.",
      "line": 91,
      "preview": "- Post-pyloric administration assumes the medication can be absorbed where it enters the GI tract"
    },
    {
      "type": "text",
      "section": "SAFE MEDICATION PRACTICES WITH EN, CONT.",
      "line": 92,
      "preview": "- Intestinal site of absorption of most medications is lacking"
    },
    {
      "type": "text",
      "section": "SAFE MEDICATION PRACTICES WITH EN, CONT.",
      "line": 93,
      "preview": "- Potential increased toxicity due to lack of degradation from gastric acid or decreased first-pass "
    },
    {
      "type": "text",
      "section": "SAFE MEDICATION PRACTICES WITH EN, CONT.",
      "line": 94,
      "preview": "- Treatment failure"
    },
    {
      "type": "text",
      "section": "SAFE MEDICATION PRACTICES WITH EN, CONT.",
      "line": 96,
      "preview": "McIntyre CM et al. AmJ Health-Syst Pharm. 2014;71:549-56."
    },
    {
      "type": "text",
      "section": "SAFE MEDICATION PRACTICES WITH EN, CONT.",
      "line": 98,
      "preview": "--- page 5 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "SAFE MEDICATION PRACTICES WITH EN, CONT.",
      "line": 100
    },
    {
      "type": "text",
      "section": "SAFE MEDICATION PRACTICES WITH EN, CONT.",
      "line": 102,
      "preview": "- Nasoduodenal"
    },
    {
      "type": "text",
      "section": "SAFE MEDICATION PRACTICES WITH EN, CONT.",
      "line": 103,
      "preview": "- Nasojejunal"
    },
    {
      "type": "text",
      "section": "SAFE MEDICATION PRACTICES WITH EN, CONT.",
      "line": 104,
      "preview": "- Jejunostomy"
    },
    {
      "type": "text",
      "section": "SAFE MEDICATION PRACTICES WITH EN, CONT.",
      "line": 105,
      "preview": "- Avoid use of aspirin and ferrous sulfate post-pylorically"
    },
    {
      "type": "text",
      "section": "SAFE MEDICATION PRACTICES WITH EN, CONT.",
      "line": 106,
      "preview": "- Require gastric acid for absorption and can only be administered into the stomach"
    },
    {
      "type": "text",
      "section": "SAFE MEDICATION PRACTICES WITH EN, CONT.",
      "line": 107,
      "preview": "- Increased absorption has occurred post-pylorically for:"
    },
    {
      "type": "text",
      "section": "SAFE MEDICATION PRACTICES WITH EN, CONT.",
      "line": 108,
      "preview": "- Ciprofloxacin, fluconazole, pravastatin, zinc, azathioprine"
    },
    {
      "type": "text",
      "section": "SAFE MEDICATION PRACTICES WITH EN, CONT.",
      "line": 109,
      "preview": "- Decreased absorption has occurred post-pylorically for:"
    },
    {
      "type": "text",
      "section": "SAFE MEDICATION PRACTICES WITH EN, CONT.",
      "line": 110,
      "preview": "- Allopurinol, baclofen, calcium, gabapentin, sirolimus"
    },
    {
      "type": "text",
      "section": "SAFE MEDICATION PRACTICES WITH EN, CONT.",
      "line": 112,
      "preview": "McIntyre CM et al. AmJ Health-Syst Pharm. 2014;71:549-56."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "SAFE MEDICATION PRACTICES WITH EN, CONT.",
      "line": 114
    },
    {
      "type": "text",
      "section": "SAFE MEDICATION PRACTICES WITH EN, CONT.",
      "line": 116,
      "preview": "- Avoid solid dosage form medications resulting in a significant change in absorption of the active "
    },
    {
      "type": "text",
      "section": "SAFE MEDICATION PRACTICES WITH EN, CONT.",
      "line": 117,
      "preview": "- Immediate release products only"
    },
    {
      "type": "text",
      "section": "SAFE MEDICATION PRACTICES WITH EN, CONT.",
      "line": 118,
      "preview": "- Evaluate each medication for its inherent solubility and release characteristics"
    },
    {
      "type": "text",
      "section": "SAFE MEDICATION PRACTICES WITH EN, CONT.",
      "line": 119,
      "preview": "- Consider alternative dosage form, drug or route of administration"
    },
    {
      "type": "text",
      "section": "SAFE MEDICATION PRACTICES WITH EN, CONT.",
      "line": 120,
      "preview": "- Enteric coated or extended/sustained release especially"
    },
    {
      "type": "text",
      "section": "SAFE MEDICATION PRACTICES WITH EN, CONT.",
      "line": 121,
      "preview": "- May lead to occluded feeding tube"
    },
    {
      "type": "text",
      "section": "SAFE MEDICATION PRACTICES WITH EN, CONT.",
      "line": 122,
      "preview": "- Increased drug toxicity if crushed"
    },
    {
      "type": "text",
      "section": "SAFE MEDICATION PRACTICES WITH EN, CONT.",
      "line": 123,
      "preview": "- Do not add medication directly to an enteral feeding formula"
    },
    {
      "type": "text",
      "section": "SAFE MEDICATION PRACTICES WITH EN, CONT.",
      "line": 125,
      "preview": "--- page 6 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "SAFE MEDICATION PRACTICES WITH EN, CONT.",
      "line": 127
    },
    {
      "type": "text",
      "section": "SAFE MEDICATION PRACTICES WITH EN, CONT.",
      "line": 129,
      "preview": "- Only crush simple compressed tablets to fine powder and mix with purified water"
    },
    {
      "type": "text",
      "section": "SAFE MEDICATION PRACTICES WITH EN, CONT.",
      "line": 130,
      "preview": "- Only open hard gelatin capsules and mix powder containing the immediate release medication with pu"
    },
    {
      "type": "text",
      "section": "SAFE MEDICATION PRACTICES WITH EN, CONT.",
      "line": 131,
      "preview": "- Provide feeding tube irrigation around the timing of drug administration"
    },
    {
      "type": "text",
      "section": "SAFE MEDICATION PRACTICES WITH EN, CONT.",
      "line": 132,
      "preview": "- Prior to medication administration, stop the enteral feeding and flush the tube with at least 15 m"
    },
    {
      "type": "text",
      "section": "SAFE MEDICATION PRACTICES WITH EN, CONT.",
      "line": 133,
      "preview": "- Administer the medication using a clean ENFIT syringe"
    },
    {
      "type": "text",
      "section": "SAFE MEDICATION PRACTICES WITH EN, CONT.",
      "line": 134,
      "preview": "- Flush the tube again with at least 15 mL water"
    },
    {
      "type": "text",
      "section": "SAFE MEDICATION PRACTICES WITH EN, CONT.",
      "line": 135,
      "preview": "- Repeat with the next medication"
    },
    {
      "type": "text",
      "section": "SAFE MEDICATION PRACTICES WITH EN, CONT.",
      "line": 136,
      "preview": "- Restart the enteral feeding in a timely manner"
    },
    {
      "type": "text",
      "section": "SAFE MEDICATION PRACTICES WITH EN, CONT.",
      "line": 138,
      "preview": "Boulatta Jlet al. JPEN J Parenter Enteral Nutr. 2017; 41(1):15-103."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "SAFE MEDICATION PRACTICES WITH EN, CONT.",
      "line": 140
    },
    {
      "type": "text",
      "section": "SAFE MEDICATION PRACTICES WITH EN, CONT.",
      "line": 142,
      "preview": "- Enteral feeding tubes with an internal diameter equal to or greater than 10 French are best for ad"
    },
    {
      "type": "text",
      "section": "SAFE MEDICATION PRACTICES WITH EN, CONT.",
      "line": 143,
      "preview": "- Tubes less than 10 French require medications in a liquid formulation with few residual solids (e."
    },
    {
      "type": "text",
      "section": "SAFE MEDICATION PRACTICES WITH EN, CONT.",
      "line": 144,
      "preview": "- Smaller tube sizes are prone to clogging"
    },
    {
      "type": "text",
      "section": "SAFE MEDICATION PRACTICES WITH EN, CONT.",
      "line": 145,
      "preview": "- Institute for Safe Medication Practices resource:"
    },
    {
      "type": "text",
      "section": "SAFE MEDICATION PRACTICES WITH EN, CONT.",
      "line": 146,
      "preview": "- Do Not Crush list"
    },
    {
      "type": "text",
      "section": "SAFE MEDICATION PRACTICES WITH EN, CONT.",
      "line": 148,
      "preview": "--- page 7 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "SAFE MEDICATION PRACTICES WITH PN",
      "line": 150
    },
    {
      "type": "text",
      "section": "SAFE MEDICATION PRACTICES WITH PN",
      "line": 152,
      "preview": "- Venous access device determines parenteral drug compatibility in the setting of PN"
    },
    {
      "type": "text",
      "section": "SAFE MEDICATION PRACTICES WITH PN",
      "line": 153,
      "preview": "- Single lumen catheters are the greatest challenge as separate IV administration of other medicatio"
    },
    {
      "type": "text",
      "section": "SAFE MEDICATION PRACTICES WITH PN",
      "line": 154,
      "preview": "- If simultaneous IV administration with PN is inevitable, utilize available IV drug compatibility r"
    },
    {
      "type": "text",
      "section": "SAFE MEDICATION PRACTICES WITH PN",
      "line": 155,
      "preview": "- Y-site administration has limited published resources with PN"
    },
    {
      "type": "text",
      "section": "SAFE MEDICATION PRACTICES WITH PN",
      "line": 156,
      "preview": "- 106 drugs evaluated with 83 deemed compatible"
    },
    {
      "type": "text",
      "section": "SAFE MEDICATION PRACTICES WITH PN",
      "line": 157,
      "preview": "- Incompatible drugs included: acyclovir, amphotericin B, haloperidol, heparin, lorazepam, ondansetr"
    },
    {
      "type": "text",
      "section": "SAFE MEDICATION PRACTICES WITH PN",
      "line": 158,
      "preview": "- Contact manufacturer(s) for new PN or ILE product compatibility"
    },
    {
      "type": "text",
      "section": "SAFE MEDICATION PRACTICES WITH PN",
      "line": 160,
      "preview": "Trissel LA et al. JPEN J Parenter Enteral Nutr. 1999; 23(2):67-74."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "MANAGING PN WITH SEPARATE ILE INFUSIONS",
      "line": 162
    },
    {
      "type": "text",
      "section": "MANAGING PN WITH SEPARATE ILE INFUSIONS",
      "line": 164,
      "preview": "- Possible threats to inadvertent PN administrations"
    },
    {
      "type": "text",
      "section": "MANAGING PN WITH SEPARATE ILE INFUSIONS",
      "line": 165,
      "preview": "- Both PN and separate ILE on same IV pole"
    },
    {
      "type": "text",
      "section": "MANAGING PN WITH SEPARATE ILE INFUSIONS",
      "line": 166,
      "preview": "- Using 2 separate pumps increases risk for rate error"
    },
    {
      "type": "text",
      "section": "MANAGING PN WITH SEPARATE ILE INFUSIONS",
      "line": 167,
      "preview": "- Double check of pump settings needed by 2nd nurse prior to start of infusions"
    },
    {
      "type": "text",
      "section": "MANAGING PN WITH SEPARATE ILE INFUSIONS",
      "line": 168,
      "preview": "- Inadequate room lighting"
    },
    {
      "type": "text",
      "section": "MANAGING PN WITH SEPARATE ILE INFUSIONS",
      "line": 169,
      "preview": "- Routinely trace lines back to source"
    },
    {
      "type": "text",
      "section": "MANAGING PN WITH SEPARATE ILE INFUSIONS",
      "line": 170,
      "preview": "- Lines confused despite color differences of IV products"
    },
    {
      "type": "text",
      "section": "MANAGING PN WITH SEPARATE ILE INFUSIONS",
      "line": 171,
      "preview": "- Confusion of rates of PN and separate ILE"
    },
    {
      "type": "text",
      "section": "MANAGING PN WITH SEPARATE ILE INFUSIONS",
      "line": 172,
      "preview": "- Omission of in-line filter placement"
    },
    {
      "type": "text",
      "section": "MANAGING PN WITH SEPARATE ILE INFUSIONS",
      "line": 174,
      "preview": "--- page 8 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "ADVANTAGES AND DISADVANTAGES OF TNA",
      "line": 176
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Advantages",
      "line": 178
    },
    {
      "type": "text",
      "section": "Advantages",
      "line": 180,
      "preview": "- $\\downarrow$ Pharmacy preparation and nursing administration time"
    },
    {
      "type": "text",
      "section": "Advantages",
      "line": 181,
      "preview": "- Only one infusion pump required"
    },
    {
      "type": "text",
      "section": "Advantages",
      "line": 182,
      "preview": "- $\\downarrow$ risk of touch contamination"
    },
    {
      "type": "text",
      "section": "Advantages",
      "line": 183,
      "preview": "- $\\downarrow$ Rate of microbial growth vs. ILE alone"
    },
    {
      "type": "text",
      "section": "Advantages",
      "line": 184,
      "preview": "- Improved oxidation of lipids"
    },
    {
      "type": "text",
      "section": "Advantages",
      "line": 186,
      "preview": "Derenski K et al. Nutr Clin Pract. 2016; 31(5):578-95."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Disadvantages",
      "line": 188
    },
    {
      "type": "text",
      "section": "Disadvantages",
      "line": 190,
      "preview": "- Macronutrients limited to one manufacturer"
    },
    {
      "type": "text",
      "section": "Disadvantages",
      "line": 191,
      "preview": "- Cannot see particulate matter"
    },
    {
      "type": "text",
      "section": "Disadvantages",
      "line": 192,
      "preview": "- Cannot infuse ILE through a 0.22 micron in-line filter"
    },
    {
      "type": "text",
      "section": "Disadvantages",
      "line": 193,
      "preview": "- Requires 1.2 micron in-line filter as for all PN formulations"
    },
    {
      "type": "text",
      "section": "Disadvantages",
      "line": 194,
      "preview": "- Risk of ILE instability"
    },
    {
      "type": "text",
      "section": "Disadvantages",
      "line": 196,
      "preview": "PHE-CPOE PN SAFETY IMPLICATIONS"
    },
    {
      "type": "text",
      "section": "Disadvantages",
      "line": 198,
      "preview": "- Prospective, observational study in a large teaching hospital with a nutrition support team; 4730 "
    },
    {
      "type": "text",
      "section": "Disadvantages",
      "line": 199,
      "preview": "- 63\\% transcription and preparation errors"
    },
    {
      "type": "text",
      "section": "Disadvantages",
      "line": 200,
      "preview": "- 35.1\\% administration errors"
    },
    {
      "type": "text",
      "section": "Disadvantages",
      "line": 201,
      "preview": "- $8 \\%$ contributed to or resulted in temporary patient harm"
    },
    {
      "type": "text",
      "section": "Disadvantages",
      "line": 202,
      "preview": "- 15.6 errors/1000 PN prescriptions"
    },
    {
      "type": "text",
      "section": "Disadvantages",
      "line": 204,
      "preview": "Sacks GS et al. Pharmacotherapy. 2009; 29:966-74."
    },
    {
      "type": "text",
      "section": "Disadvantages",
      "line": 206,
      "preview": "Percentage of PN Errors"
    },
    {
      "type": "image",
      "section": "Disadvantages",
      "line": 207,
      "content": "![img-1.jpeg](images/f8bb9afc70c15cdf.png)"
    },
    {
      "type": "text",
      "section": "Disadvantages",
      "line": 209,
      "preview": "--- page 9 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "POST-CPOE PN SAFETY IMPLICATIONS",
      "line": 211
    },
    {
      "type": "text",
      "section": "POST-CPOE PN SAFETY IMPLICATIONS",
      "line": 213,
      "preview": "- Observational study in a 350-bed urban pediatric hospital, 84,503 prescriptions for PN reviewed an"
    },
    {
      "type": "text",
      "section": "POST-CPOE PN SAFETY IMPLICATIONS",
      "line": 214,
      "preview": "- 95\\% related to administration"
    },
    {
      "type": "text",
      "section": "POST-CPOE PN SAFETY IMPLICATIONS",
      "line": 215,
      "preview": "- $9.1 \\%$ contributed to or resulted in temporary patient harm"
    },
    {
      "type": "text",
      "section": "POST-CPOE PN SAFETY IMPLICATIONS",
      "line": 216,
      "preview": "- 2.7 errors/1000 PN prescriptions"
    },
    {
      "type": "text",
      "section": "POST-CPOE PN SAFETY IMPLICATIONS",
      "line": 218,
      "preview": "MacKay Met al. Nutr Clin Pract. 2016;31:195-206."
    },
    {
      "type": "image",
      "section": "POST-CPOE PN SAFETY IMPLICATIONS",
      "line": 219,
      "content": "![img-2.jpeg](images/74de5a2ef7d33712.png)"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "SELF-ASSESSMENT \\#1",
      "line": 221
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#1",
      "line": 223,
      "preview": "A 61-year-old male with Type 2 diabetes mellitus and benign prostatic hypertrophy is admitted with u"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#1",
      "line": 224,
      "preview": "A. Tamsulosin 0.4 mg daily"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#1",
      "line": 225,
      "preview": "B. Doxazosin 2 mg daily"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#1",
      "line": 226,
      "preview": "C. Metformin ER 2000 mg daily"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#1",
      "line": 227,
      "preview": "D. Metformin ER 500 mg TID"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#1",
      "line": 229,
      "preview": "--- page 10 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "SELF-ASSESSMENT \\#1",
      "line": 231
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#1",
      "line": 233,
      "preview": "A 61-year-old male with Type 2 diabetes mellitus and benign prostatic hypertrophy is admitted with u"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#1",
      "line": 234,
      "preview": "A. Tamsulosin 0.4 mg daily"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#1",
      "line": 235,
      "preview": "B. Doxazosin 2 mg daily"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#1",
      "line": 236,
      "preview": "C. Metformin ER 2000 mg daily"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#1",
      "line": 237,
      "preview": "D. Metformin ER 500 mg TID"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "SELF-ASSESSMENT \\#2",
      "line": 239
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#2",
      "line": 241,
      "preview": "A 55-year-old female with acute myelogenous leukemia and typhlitis is receiving parenteral nutrition"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#2",
      "line": 242,
      "preview": "A. Acyclovir"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#2",
      "line": 243,
      "preview": "B. Amphotericin B"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#2",
      "line": 244,
      "preview": "C. Ondansetron"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#2",
      "line": 245,
      "preview": "D. Piperacillin/Tazobactam"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#2",
      "line": 247,
      "preview": "--- page 11 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "SELF-ASSESSMENT \\#2",
      "line": 249
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#2",
      "line": 251,
      "preview": "A 55-year-old female with acute myelogenous leukemia and typhlitis is receiving parenteral nutrition"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#2",
      "line": 252,
      "preview": "A. Acyclovir"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#2",
      "line": 253,
      "preview": "B. Amphotericin B"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#2",
      "line": 254,
      "preview": "C. Ondansetron"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#2",
      "line": 255,
      "preview": "D. Piperacillin/Tazobactam"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "CONCLUSIONS",
      "line": 257
    },
    {
      "type": "text",
      "section": "CONCLUSIONS",
      "line": 259,
      "preview": "- Safe use of medication administration via an enteral feeding tube requires:"
    },
    {
      "type": "text",
      "section": "CONCLUSIONS",
      "line": 260,
      "preview": "- Knowledge of proximal end of tube in Gl tract for drug absorption"
    },
    {
      "type": "text",
      "section": "CONCLUSIONS",
      "line": 261,
      "preview": "- Osmolality of medication and use of other excipients such as sorbitol"
    },
    {
      "type": "text",
      "section": "CONCLUSIONS",
      "line": 262,
      "preview": "- Dosage form that is immediate release"
    },
    {
      "type": "text",
      "section": "CONCLUSIONS",
      "line": 263,
      "preview": "- Adequate flushing of the feeding tube before and after medication"
    },
    {
      "type": "text",
      "section": "CONCLUSIONS",
      "line": 264,
      "preview": "- Safe use of medication administration via Y-site with PN requires:"
    },
    {
      "type": "text",
      "section": "CONCLUSIONS",
      "line": 265,
      "preview": "- Confirmed drug compatibility (e.g., Handbook of Injectable Drugs)"
    },
    {
      "type": "text",
      "section": "CONCLUSIONS",
      "line": 266,
      "preview": "- Other IV site or enteral options if no compatibility information exists"
    },
    {
      "type": "text",
      "section": "CONCLUSIONS",
      "line": 267,
      "preview": "- Use of PN with separate ILE infusion increases the risk of administration errors"
    },
    {
      "type": "text",
      "section": "CONCLUSIONS",
      "line": 269,
      "preview": "--- page 12 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "REFERENCES",
      "line": 271
    },
    {
      "type": "text",
      "section": "REFERENCES",
      "line": 273,
      "preview": "- Boullata JI, Carrera AL, Harvey L et al. A.S.P.E.N. safe practices for enteral nutrition therapy. "
    },
    {
      "type": "text",
      "section": "REFERENCES",
      "line": 274,
      "preview": "- Derenski K, Catlin J, Allen L. Parenteral nutrition basics for the clinician caring for the adult "
    },
    {
      "type": "text",
      "section": "REFERENCES",
      "line": 275,
      "preview": "- MacKay M, Anderson C, Boehme S et al. Frequency and severity of parenteral nutrition medication er"
    },
    {
      "type": "text",
      "section": "REFERENCES",
      "line": 276,
      "preview": "- McIntyre CM, Monk HM. Medication absorption considerations in patients with postpyloric enteral fe"
    },
    {
      "type": "text",
      "section": "REFERENCES",
      "line": 277,
      "preview": "- Sacks GS, Rough S, Kudsk KA. Frequency and severity of harm of medication errors related to the pa"
    },
    {
      "type": "text",
      "section": "REFERENCES",
      "line": 279,
      "preview": "NUTRITION SUPPORT CERTIFICATE"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "REFERENCES, CONT.",
      "line": 281
    },
    {
      "type": "text",
      "section": "REFERENCES, CONT.",
      "line": 283,
      "preview": "- Simmons D, Symes L, Guenter P et al. Tubing misconnections: Normalization of deviance. Nutr Clin P"
    },
    {
      "type": "text",
      "section": "REFERENCES, CONT.",
      "line": 284,
      "preview": "- Trissel LA, Gilbert DL, Martinez JF et al. Compatibility of medications with 3-in-1 parenteral nut"
    },
    {
      "type": "text",
      "section": "REFERENCES, CONT.",
      "line": 286,
      "preview": "--- page 13 ---"
    },
    {
      "type": "text",
      "section": "REFERENCES, CONT.",
      "line": 288,
      "preview": "NUTRITION SUPPORT CERTIFICATE"
    },
    {
      "type": "text",
      "section": "REFERENCES, CONT.",
      "line": 290,
      "preview": "--- page 14 ---"
    },
    {
      "type": "image",
      "section": "REFERENCES, CONT.",
      "line": 292,
      "content": "![img-3.jpeg](images/f88d6ef789286d4c.png)"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Todd W. Canada, Pharm.D., BCNSP, BCCCP, FASHP, FTSHP, FASPEN",
      "line": 294
    },
    {
      "type": "text",
      "section": "Todd W. Canada, Pharm.D., BCNSP, BCCCP, FASHP, FTSHP, FASPEN",
      "line": 296,
      "preview": "Clinical Pharmacy Services Manager"
    },
    {
      "type": "text",
      "section": "Todd W. Canada, Pharm.D., BCNSP, BCCCP, FASHP, FTSHP, FASPEN",
      "line": 297,
      "preview": "Nutrition Support Team Coordinator"
    },
    {
      "type": "text",
      "section": "Todd W. Canada, Pharm.D., BCNSP, BCCCP, FASHP, FTSHP, FASPEN",
      "line": 298,
      "preview": "University of Texas MD Anderson Cancer Center"
    },
    {
      "type": "text",
      "section": "Todd W. Canada, Pharm.D., BCNSP, BCCCP, FASHP, FTSHP, FASPEN",
      "line": 299,
      "preview": "Houston, Texas"
    },
    {
      "type": "text",
      "section": "Todd W. Canada, Pharm.D., BCNSP, BCCCP, FASHP, FTSHP, FASPEN",
      "line": 300,
      "preview": "Todd W. Canada serves as a clinical pharmacy services manager and nutrition support team coordinator"
    },
    {
      "type": "text",
      "section": "Todd W. Canada, Pharm.D., BCNSP, BCCCP, FASHP, FTSHP, FASPEN",
      "line": 302,
      "preview": "Dr. Canada completed a specialized residency in Critical Care / Nutrition Support at the University "
    },
    {
      "type": "text",
      "section": "Todd W. Canada, Pharm.D., BCNSP, BCCCP, FASHP, FTSHP, FASPEN",
      "line": 304,
      "preview": "--- page 15 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Relevant Financial Relationship Disclosure",
      "line": 306
    },
    {
      "type": "text",
      "section": "Relevant Financial Relationship Disclosure",
      "line": 308,
      "preview": "In accordance with our accreditor\u2019s Standards of Integrity and Independence in Accredited Continuing"
    },
    {
      "type": "text",
      "section": "Relevant Financial Relationship Disclosure",
      "line": 310,
      "preview": "An ineligible company is any entity producing, marketing, re-selling, or distributing health care go"
    },
    {
      "type": "text",
      "section": "Relevant Financial Relationship Disclosure",
      "line": 312,
      "preview": "The following persons in control of this activity\u2019s content have relevant financial relationships:"
    },
    {
      "type": "text",
      "section": "Relevant Financial Relationship Disclosure",
      "line": 314,
      "preview": "- Phil Ayers: Fresenius Kabi, consultant and speaker"
    },
    {
      "type": "text",
      "section": "Relevant Financial Relationship Disclosure",
      "line": 315,
      "preview": "- David Evans: Fresenius Kabi, consultant and speaker; Abbott Laboratories, consultant and speaker; "
    },
    {
      "type": "text",
      "section": "Relevant Financial Relationship Disclosure",
      "line": 316,
      "preview": "- Andrew Mays: Fresenius Kabi, speaker"
    },
    {
      "type": "text",
      "section": "Relevant Financial Relationship Disclosure",
      "line": 317,
      "preview": "- Jay Mirtallo: Fresenius Kabi, consultant"
    },
    {
      "type": "text",
      "section": "Relevant Financial Relationship Disclosure",
      "line": 318,
      "preview": "- Kris Mogensen: Baxter, speaker; ThriveRx, advisory board; Pfizer, advisory board"
    },
    {
      "type": "text",
      "section": "Relevant Financial Relationship Disclosure",
      "line": 320,
      "preview": "All other persons in control of content do not have any relevant financial relationships with an ine"
    },
    {
      "type": "text",
      "section": "Relevant Financial Relationship Disclosure",
      "line": 322,
      "preview": "As required by the Standards of Integrity and Independence in Accredited Continuing Education defini"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Methods and CE Requirements",
      "line": 324
    },
    {
      "type": "text",
      "section": "Methods and CE Requirements",
      "line": 326,
      "preview": "This online activity consists of a combined total of 12 learning modules. Pharmacists and physicians"
    },
    {
      "type": "text",
      "section": "Methods and CE Requirements",
      "line": 328,
      "preview": "Participants must participate in the entire activity, complete the evaluation and all required compo"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Important Note \u2013 ACPE 60 Day Deadline:",
      "line": 330
    },
    {
      "type": "text",
      "section": "Important Note \u2013 ACPE 60 Day Deadline:",
      "line": 332,
      "preview": "Per ACPE requirements, CPE credit must be claimed within 60 days of being earned. To verify that you"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "System Technical Requirements",
      "line": 334
    },
    {
      "type": "text",
      "section": "System Technical Requirements",
      "line": 336,
      "preview": "Courses and learning activities are delivered via your Web browser and Acrobat PDF. Users should hav"
    },
    {
      "type": "text",
      "section": "System Technical Requirements",
      "line": 338,
      "preview": "View Frequently Asked Questions for more information."
    }
  ],
  "images": [
    {
      "sha_name": "412f1b1b557f1ba0.png",
      "original_ref": "img-0.jpeg",
      "page": 1,
      "relative_path": "images/412f1b1b557f1ba0.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/7_AdministrationofNutritionSupport,Part2/images/412f1b1b557f1ba0.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "412f1b1b557f1ba0"
    },
    {
      "sha_name": "f8bb9afc70c15cdf.png",
      "original_ref": "img-1.jpeg",
      "page": 8,
      "relative_path": "images/f8bb9afc70c15cdf.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/7_AdministrationofNutritionSupport,Part2/images/f8bb9afc70c15cdf.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "f8bb9afc70c15cdf"
    },
    {
      "sha_name": "74de5a2ef7d33712.png",
      "original_ref": "img-2.jpeg",
      "page": 9,
      "relative_path": "images/74de5a2ef7d33712.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/7_AdministrationofNutritionSupport,Part2/images/74de5a2ef7d33712.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "74de5a2ef7d33712"
    },
    {
      "sha_name": "f88d6ef789286d4c.png",
      "original_ref": "img-3.jpeg",
      "page": 14,
      "relative_path": "images/f88d6ef789286d4c.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/7_AdministrationofNutritionSupport,Part2/images/f88d6ef789286d4c.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "f88d6ef789286d4c"
    }
  ],
  "extraction": {
    "ocr_model": "mistral-ocr-latest",
    "request_id": "local-1754696164",
    "ts": "2025-08-08T23:36:04.492121+00:00"
  }
}